SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and ...
GSK plc GSK announced that it has entered into a definitive agreement to acquire California-based biotech RAPT Therapeutics RAPT for an estimated aggregate equity value of $2.2 billion. The impending ...
Investors might want to bet on Rapt Therapeutics (RAPT), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...
On Thursday, RAPT Therapeutics Inc. (NASDAQ:RAPT) announced that it has decided to close and unblind both its Phase 2b trial of zelnecirnon (RPT193) in atopic dermatitis (AD) and its Phase 2a trial of ...
RAPT Therapeutics Inc. shares RAPT dropped more than 60% premarket on Tuesday after the company said regulators have hit pause on two clinical trials of its experimental inflammation treatment due to ...
OrbiMed Advisors increased its position in RAPT Therapeutics by 556,273 shares during the fourth quarter; the estimated trade size was $17.28 million based on quarterly average pricing. The ...
Feb 20 (Reuters) - Rapt Therapeutics (RAPT.O), opens new tab said on Tuesday the U.S. FDA had placed on hold two mid-stage trials of the company's drug to treat eczema and asthma, after liver failure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results